Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from G1 Therapeutics (GTHX).
G1 Therapeutics, Inc. announced disappointing results for their Phase 3 trial, PRESERVE 2, which tested trilaciclib with chemotherapy agents in treating metastatic triple negative breast cancer. The trial failed to meet the primary goal of improving overall survival, a significant setback for the company’s leading drug candidate. This news is likely to impact investor confidence and the company’s stock value.
For an in-depth examination of GTHX stock, go to TipRanks’ Stock Analysis page.
